Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 289 to 293 of 293 entries
Sorted by: Best Match Show Resources per page
Fetal Complications in COVID-19 Infected Pregnant Woman: A Systematic Review and Meta-Analysis.

Avicenna journal of medicine

Agolli A, Agolli O, Velazco DFS, Ahammed MR, Patel M, Cardona-Guzman J, Garimella R, Rummaneethorn N, Bista S, Abreu R, Czapp N, Garcia M.
PMID: 34881203
Avicenna J Med. 2021 Nov 15;11(4):200-209. doi: 10.1055/s-0041-1736540. eCollection 2021 Oct.

No abstract available.

Cite
Agolli A, Agolli O, Velazco DFS, et al. Fetal Complications in COVID-19 Infected Pregnant Woman: A Systematic Review and Meta-Analysis. Avicenna J Med. 2021;11(4):200-209doi: 10.1055/s-0041-1736540.
Agolli, A., Agolli, O., Velazco, D. F. S., Ahammed, M. R., Patel, M., Cardona-Guzman, J., Garimella, R., Rummaneethorn, N., Bista, S., Abreu, R., Czapp, N., & Garcia, M. (2021). Fetal Complications in COVID-19 Infected Pregnant Woman: A Systematic Review and Meta-Analysis. Avicenna journal of medicine, 11(4), 200-209. https://doi.org/10.1055/s-0041-1736540
Agolli, Arjola, et al. "Fetal Complications in COVID-19 Infected Pregnant Woman: A Systematic Review and Meta-Analysis." Avicenna journal of medicine vol. 11,4 (2021): 200-209. doi: https://doi.org/10.1055/s-0041-1736540
Agolli A, Agolli O, Velazco DFS, Ahammed MR, Patel M, Cardona-Guzman J, Garimella R, Rummaneethorn N, Bista S, Abreu R, Czapp N, Garcia M. Fetal Complications in COVID-19 Infected Pregnant Woman: A Systematic Review and Meta-Analysis. Avicenna J Med. 2021 Nov 15;11(4):200-209. doi: 10.1055/s-0041-1736540. eCollection 2021 Oct. PMID: 34881203; PMCID: PMC8648404.
Copy Download .nbib Format: NLM
Nanomaterials to Fight Cancer: An Overview on Their Multifunctional Exploitability.

Journal of nanoscience and nanotechnology

Terracciano R, Demarchi D, Ruo Roch M, Aiassa S, Pagana G.
PMID: 33653442
J Nanosci Nanotechnol. 2021 May 01;21(5):2760-2777. doi: 10.1166/jnn.2021.19061.

In recent years the worldwide research community has highlighted innumerable benefits of nanomaterials in cancer detection and therapy. Nevertheless, the development of cancer nanomedicines and other bionanotechnology requires a huge amount of considerations about the interactions of nanomaterials and...

Cite
Terracciano R, Demarchi D, Ruo Roch M, et al. Nanomaterials to Fight Cancer: An Overview on Their Multifunctional Exploitability. J Nanosci Nanotechnol. 2021;21(5):2760-2777doi: 10.1166/jnn.2021.19061.
Terracciano, R., Demarchi, D., Ruo Roch, M., Aiassa, S., & Pagana, G. (2021). Nanomaterials to Fight Cancer: An Overview on Their Multifunctional Exploitability. Journal of nanoscience and nanotechnology, 21(5), 2760-2777. https://doi.org/10.1166/jnn.2021.19061
Terracciano, Rossana, et al. "Nanomaterials to Fight Cancer: An Overview on Their Multifunctional Exploitability." Journal of nanoscience and nanotechnology vol. 21,5 (2021): 2760-2777. doi: https://doi.org/10.1166/jnn.2021.19061
Terracciano R, Demarchi D, Ruo Roch M, Aiassa S, Pagana G. Nanomaterials to Fight Cancer: An Overview on Their Multifunctional Exploitability. J Nanosci Nanotechnol. 2021 May 01;21(5):2760-2777. doi: 10.1166/jnn.2021.19061. PMID: 33653442.
Copy Download .nbib Format: NLM
Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis.

Cureus

Bastakoti S, Kunwar S, Poudel S, Quinonez J, Bista S, Singh N, Jha V, Ruxmohan S, Paesani S, Cueva W, Michel J.
PMID: 34909332
Cureus. 2021 Nov 09;13(11):e19416. doi: 10.7759/cureus.19416. eCollection 2021 Nov.

Myasthenia gravis affects the neuromuscular junction of the skeletal muscles. It results in muscle weakness involving skeletal muscles (diaphragm, extraocular muscles) and myasthenic crisis. Treatment options for myasthenia gravis management have expanded, including azathioprine, corticosteroids, plasma exchange, and tacrolimus....

Cite
Bastakoti S, Kunwar S, Poudel S, et al. Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis. Cureus. 2021;13(11):e19416doi: 10.7759/cureus.19416.
Bastakoti, S., Kunwar, S., Poudel, S., Quinonez, J., Bista, S., Singh, N., Jha, V., Ruxmohan, S., Paesani, S., Cueva, W., & Michel, J. (2021). Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis. Cureus, 13(11), e19416. https://doi.org/10.7759/cureus.19416
Bastakoti, Sanjiv, et al. "Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis." Cureus vol. 13,11 (2021): e19416. doi: https://doi.org/10.7759/cureus.19416
Bastakoti S, Kunwar S, Poudel S, Quinonez J, Bista S, Singh N, Jha V, Ruxmohan S, Paesani S, Cueva W, Michel J. Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis. Cureus. 2021 Nov 09;13(11):e19416. doi: 10.7759/cureus.19416. eCollection 2021 Nov. PMID: 34909332; PMCID: PMC8660595.
Copy Download .nbib Format: NLM
Improving adoption of technologies and interventions for increasing supply of quality livestock feed in low- and middle-income countries.

Global food security

Balehegn M, Duncan A, Tolera A, Ayantunde AA, Issa S, Karimou M, Zampaligré N, André K, Gnanda I, Varijakshapanicker P, Kebreab E, Dubeux J, Boote K, Minta M, Feyissa F, Adesogan AT.
PMID: 33324534
Glob Food Sec. 2020 Sep;26:100372. doi: 10.1016/j.gfs.2020.100372.

The global increase in the demand for and production of animal-source foods (four-to five-fold increase between 1960 and 2015), which has been mostly concentrated in low- and middle-income countries (LMIC), provides smallholder livestock producers with an opportunity for improving...

Cite
Balehegn M, Duncan A, Tolera A, et al. Improving adoption of technologies and interventions for increasing supply of quality livestock feed in low- and middle-income countries. Glob Food Sec. 2020;26:100372doi: 10.1016/j.gfs.2020.100372.
Balehegn, M., Duncan, A., Tolera, A., Ayantunde, A. A., Issa, S., Karimou, M., Zampaligré, N., André, K., Gnanda, I., Varijakshapanicker, P., Kebreab, E., Dubeux, J., Boote, K., Minta, M., Feyissa, F., & Adesogan, A. T. (2020). Improving adoption of technologies and interventions for increasing supply of quality livestock feed in low- and middle-income countries. Global food security, 26100372. https://doi.org/10.1016/j.gfs.2020.100372
Balehegn, Mulubrhan, et al. "Improving adoption of technologies and interventions for increasing supply of quality livestock feed in low- and middle-income countries." Global food security vol. 26 (2020): 100372. doi: https://doi.org/10.1016/j.gfs.2020.100372
Balehegn M, Duncan A, Tolera A, Ayantunde AA, Issa S, Karimou M, Zampaligré N, André K, Gnanda I, Varijakshapanicker P, Kebreab E, Dubeux J, Boote K, Minta M, Feyissa F, Adesogan AT. Improving adoption of technologies and interventions for increasing supply of quality livestock feed in low- and middle-income countries. Glob Food Sec. 2020 Sep;26:100372. doi: 10.1016/j.gfs.2020.100372. PMID: 33324534; PMCID: PMC7726233.
Copy Download .nbib Format: NLM
Inflammatory breast cancer: is it really a separate entity?.

Ecancermedicalscience

Bastawisy A, Gaafar R, Eisa S, Amira G, Helal M.
PMID: 22570674
Ecancermedicalscience. 2012;6:250. doi: 10.3332/ecancer.2012.250. Epub 2012 Apr 12.

BACKGROUND: Inflammatory breast cancer (IBC) is the most aggressive form of primary breast carcinoma and is associated with a dismal outcome despite the availability of multi-modality treatment options.PATIENTS AND METHODS: This is a prospective case control study comparing two...

Cite
Bastawisy A, Gaafar R, Eisa S, et al. Inflammatory breast cancer: is it really a separate entity?. Ecancermedicalscience. 2012;6:250doi: 10.3332/ecancer.2012.250.
Bastawisy, A., Gaafar, R., Eisa, S., Amira, G., & Helal, M. (2012). Inflammatory breast cancer: is it really a separate entity?. Ecancermedicalscience, 6250. https://doi.org/10.3332/ecancer.2012.250
Bastawisy, As, et al. "Inflammatory breast cancer: is it really a separate entity?." Ecancermedicalscience vol. 6 (2012): 250. doi: https://doi.org/10.3332/ecancer.2012.250
Bastawisy A, Gaafar R, Eisa S, Amira G, Helal M. Inflammatory breast cancer: is it really a separate entity?. Ecancermedicalscience. 2012;6:250. doi: 10.3332/ecancer.2012.250. Epub 2012 Apr 12. PMID: 22570674; PMCID: PMC3345939.
Copy Download .nbib Format: NLM
Showing 289 to 293 of 293 entries